Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.48 |
| ▸ | FAP | Q12884 | 3/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9713852 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL6870444 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL10722960 | 0.78 | FFAR2 (0.54) | PREP | |
| SCHEMBL4799439 | 0.78 | FFAR2 (0.54) | PREP | |
| SCHEMBL10794375 | 0.76 | DPP4 (0.46) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8291743 | 0.76 | DPP4 (0.46) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL9370167 | 0.75 | FFAR2 (0.43) | PREP | |
| SCHEMBL9732210 | 0.75 | DPP4 (0.45) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL9732206 | 0.75 | DPP4 (0.45) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL10793158 | 0.73 | DPP4 (0.49) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288565-B2 | Process for the synthesis of (2S,3AR,7AS)-octahydro-1H-indole carboxylic acid as an intermediate for trandolapril | ABBOTT LABORATORIES (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110065930-A1 | PROCESS FOR THE SYNTHESIS OF (2S,3AR,7AS)-OCTAHYDRO-1H-INDOLE CARBOXYLIC ACID AS AN INTERMEDIATE FOR TRANDOLAPRIL | ABBOTT LABORATORIES (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065930-A1 | PROCESS FOR THE SYNTHESIS OF (2S,3AR,7AS)-OCTAHYDRO-1H-INDOLE CARBOXYLIC ACID AS AN INTERMEDIATE FOR TRANDOLAPRIL | ABBOTT LABORATORIES (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065930-A1 | PROCESS FOR THE SYNTHESIS OF (2S,3AR,7AS)-OCTAHYDRO-1H-INDOLE CARBOXYLIC ACID AS AN INTERMEDIATE FOR TRANDOLAPRIL | TPH1, HTR1A, HTR3A | DPP4 1345/4885DPP8 1580/4885DPP9 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.